SCHEDULE: FMR LLC Discloses Stake in Kymera Therapeutics

FMR LLC and Abigail P. Johnson have reported a significant beneficial ownership stake of 14.3% in Kymera Therapeutics Inc. as of March 31, 2026.

Summary

• FMR LLC, along with Abigail P. Johnson, has filed a Schedule 13G, indicating a beneficial ownership of 11,681,450.45 shares of Kymera Therapeutics Inc. common stock.
• This ownership represents 14.3% of the class of securities.
• The filing is an amendment (Amendment No. 4) to a previous filing.
• The reporting persons are FMR LLC and Abigail P. Johnson.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment company (IN).
• The filing date for this statement is March 31, 2026, with the report filed on May 5, 2026.
• Fidelity Management & Research Company LLC and Strategic Advisers LLC are identified as subsidiaries of FMR LLC that beneficially own 5% or greater of the security class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing ownership stakes rather than new financial performance or strategic shifts.

Positives

• FMR LLC and Abigail P. Johnson have a substantial beneficial ownership stake of 14.3% in Kymera Therapeutics, indicating significant investor confidence.
• The filing confirms a large holding, which could be interpreted as a positive signal for the company's market position.

Negatives

• The filing does not contain any negative financial results or operational challenges for Kymera Therapeutics.

Risks

• The filing does not explicitly mention any risks related to Kymera Therapeutics' operations or market position.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Kymera Therapeutics.

Industry Context

StockSavvy.ai notes that significant stake disclosures by large investment firms like FMR LLC in biotechnology companies like Kymera Therapeutics are common and often reflect strategic investment decisions based on the company's pipeline and market potential.

Stakeholder Impact

• Shareholders may view the significant stake held by FMR LLC as a sign of institutional support for Kymera Therapeutics.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership stake in Kymera Therapeutics.

Key Dates

Keywords

Kymera Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment Company, Holding Company, SEC Filing, Fidelity